Years after Cubist buyout, Merck scores a new Zerbaxa indication. Can it jump-start sales?

Shortly after Merck bought Cubist, it lost a patent fight over the antibiotic specialist's biggest drug, Cubicin. And that took a big bite out of Cubicin's long-term sales prospects. But now, Merck's got the next-gen antibiotic out of that deal—Zerbaxa—and just won it a brand-new use.